CJC-1295
CJC-1295 (with or without DAC)
A synthetic analogue of growth hormone-releasing hormone (GHRH). Available in two forms: with DAC (Drug Affinity Complex) for extended half-life, and without DAC for pulsatile release.
Mechanism of Action
CJC-1295 binds to GHRH receptors in the pituitary gland, stimulating the release of growth hormone. The DAC version binds to albumin in the bloodstream, extending its half-life to approximately 8 days. Without DAC, it produces a more natural pulsatile GH release pattern.
Health Claims & Evidence
Significantly increases GH and IGF-1 levels
Supports lean muscle mass and fat loss
Improves sleep quality and recovery
Anti-aging effects via GH restoration
Short-Term Effects
Improved sleep, increased appetite, mild water retention. GH and IGF-1 elevations measurable within days.
Long-Term Effects
Improved body composition, skin quality, and recovery over months of use.
Side Effects
Water retention, tingling in extremities, increased hunger. Potential for insulin resistance at high doses.
Contraindications
Avoid with active malignancies. Use with caution in diabetics due to IGF-1 effects on insulin sensitivity.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
CJC-1295 increases GH and IGF-1 in healthy adults
Teichman et al. · Journal of Clinical Endocrinology & Metabolism · 2006
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on CJC-1295 and related peptides, and prepare an educational research summary.
Explore Research